Breaking News Instant updates and real-time market news.

SAGE

Sage Therapeutics

$164.28

-2.61 (-1.56%)

08:37
04/25/19
04/25
08:37
04/25/19
08:37

Sage Therapeutics initiated with a Buy at Jefferies

Jefferies analyst Andrew Tsai started Sage Therapeutics with a Buy rating and $195 price target. The analyst views Sage as "one of the cleaner, de-risked growth stories currently in biotech." The company is reshaping the depression-treatment paradigm, particularly given Zulresso and next-gen oral SAGE-217, Tsai tells investors in a research note. His doctor checks suggest SAGE-217's sales opportunity could be $4B-$6B, which he notes is likely above consensus.

  • 02

    May

  • 03

    May

  • 06

    May

SAGE Sage Therapeutics
$164.28

-2.61 (-1.56%)

02/19/19
PIPR
02/19/19
NO CHANGE
Target $206
PIPR
Overweight
Piper sees 'significant unrealized value' in shares of Sage Therapeutics
Piper Jaffray analyst Danielle Brill keeps an Overweight rating on Sage Therapeutics with a $206 price target after the company reported fiscal 2018 results and an update on its pipeline. Enrollment in the SAGE-217 pivotal Phase 3 major depressive disorder trial is reportedly going well and top-line data are now expected by Q4 of 2019 or Q1 of 2020, Brill tells investors in a post-earnings research note. The analyst sees "significant unrealized value" for SAGE-217 and expects "various upcoming catalysts" to drive Sage shares higher.
02/22/19
GUGG
02/22/19
INITIATION
Target $205
GUGG
Buy
Sage Therapeutics initiated with a Buy at Guggenheim
Guggenheim analyst Yatin Suneja initiated Sage Therapeutics with a Buy rating and $205 price target, as he believes Zulresso and SAGE-217 have generated impressive data in PPD and MDD. The analysts, who thinks those drugs "have the potential to change the treatment paradigm for treating mood disorders," projects Zulresso and SAGE-217 could generate sales in the $3B-$5B range.
03/20/19
PIPR
03/20/19
NO CHANGE
Target $206
PIPR
Overweight
Sage Therapeutics approval in-line with expectations, says Piper Jaffray
Piper Jaffray analyst Danielle Brill says FDA approval of Sage Therapeutics' Zulresso for postpartum depression, product labeling, and gross pricing of $34,000 are "entirely in-line with expectations." The analyst continues to believe the opportunity of a 60-hour intravenous infusion with restricted use is modest at $300M in peak sales. However, the commercial footprint Sage can establish with Zulresso should position the company well for maximal success with SAGE-217 in the postpartum depression setting, Brill tells investors in a research note. She reiterates an Overweight rating on the shares with a $206 price target.
03/20/19
HCWC
03/20/19
NO CHANGE
Target $254
HCWC
Buy
Ligand receives royalty on sales of Zulresso, says H.C. Wainwright
H.C. Wainwright analyst Joseph Pantginis points out that Ligand Pharmaceuticals (LGND) is entitled to a 3% royalty on the sales of Sage Therapeutics' (SAGE) Zulresso, which just received FDA approval. The approval also provides Ligand with a $3M milestone payment, Pantginis tells investors in a research note. The analyst thinks Zulresso "should maintain a comfortable niche" and he reiterates a Buy rating on Ligand with a $254 price target.

TODAY'S FREE FLY STORIES

PAYS

Paysign

$12.70

0.165 (1.32%)

05:39
06/17/19
06/17
05:39
06/17/19
05:39
Downgrade
Paysign rating change  »

Paysign downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CTVA

Corteva

$25.20

0.23 (0.92%)

05:37
06/17/19
06/17
05:37
06/17/19
05:37
Upgrade
Corteva rating change  »

Deutsche Bank sees better…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RTLR

Rattler Midstream

$19.21

-0.195 (-1.01%)

05:32
06/17/19
06/17
05:32
06/17/19
05:32
Initiation
Rattler Midstream initiated  »

Rattler Midstream…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CMCM

Cheetah Mobile

$3.76

-0.21 (-5.29%)

05:28
06/17/19
06/17
05:28
06/17/19
05:28
Recommendations
Cheetah Mobile analyst commentary  »

Cheetah Mobile price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AKBA

Akebia

$4.09

-0.19 (-4.44%)

, FGEN

FibroGen

$40.63

-0.72 (-1.74%)

05:26
06/17/19
06/17
05:26
06/17/19
05:26
Recommendations
Akebia, FibroGen analyst commentary  »

Piper says buy Akebia…

AKBA

Akebia

$4.09

-0.19 (-4.44%)

FGEN

FibroGen

$40.63

-0.72 (-1.74%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VEOEY

Veolia Environment

$0.00

(0.00%)

05:22
06/17/19
06/17
05:22
06/17/19
05:22
Initiation
Veolia Environment initiated  »

Veolia Environment…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SZEVY

Suez

$0.00

(0.00%)

05:21
06/17/19
06/17
05:21
06/17/19
05:21
Initiation
Suez initiated  »

Suez initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EONGY

E.ON

$0.00

(0.00%)

05:21
06/17/19
06/17
05:21
06/17/19
05:21
Initiation
E.ON initiated  »

E.ON initiated with a…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

RWEOY

RWE AG

$0.00

(0.00%)

05:20
06/17/19
06/17
05:20
06/17/19
05:20
Initiation
RWE AG initiated  »

RWE AG initiated with an…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

05:20
06/17/19
06/17
05:20
06/17/19
05:20
General news
FX Action: USD-JPY has settled lower after eking out a six-day high »

FX Action: USD-JPY has…

UUGRY

United Utilities

$0.00

(0.00%)

05:19
06/17/19
06/17
05:19
06/17/19
05:19
Initiation
United Utilities initiated  »

United Utilities…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

STRNY

Severn Trent

$0.00

(0.00%)

05:18
06/17/19
06/17
05:18
06/17/19
05:18
Initiation
Severn Trent initiated  »

Severn Trent initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PEGRF

Pennon Group

$0.00

(0.00%)

05:18
06/17/19
06/17
05:18
06/17/19
05:18
Initiation
Pennon Group initiated  »

Pennon Group initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EGFEY

EFG Eurobank

$0.00

(0.00%)

05:16
06/17/19
06/17
05:16
06/17/19
05:16
Downgrade
EFG Eurobank rating change  »

EFG Eurobank downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NBG

National Bank of Greece

$0.00

(0.00%)

05:16
06/17/19
06/17
05:16
06/17/19
05:16
Downgrade
National Bank of Greece rating change  »

National Bank of Greece…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NGG

National Grid

$52.56

0.635 (1.22%)

05:14
06/17/19
06/17
05:14
06/17/19
05:14
Initiation
National Grid initiated  »

National Grid initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TEL

TE Connectivity

$90.67

-1.44 (-1.56%)

05:12
06/17/19
06/17
05:12
06/17/19
05:12
Downgrade
TE Connectivity rating change  »

TE Connectivity…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

ST

Sensata

$45.84

-1.285 (-2.73%)

05:12
06/17/19
06/17
05:12
06/17/19
05:12
Downgrade
Sensata rating change  »

Sensata downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

APH

Amphenol

$94.30

-2.64 (-2.72%)

05:12
06/17/19
06/17
05:12
06/17/19
05:12
Downgrade
Amphenol rating change  »

Amphenol downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

SAP

SAP

$127.69

-1.11 (-0.86%)

05:10
06/17/19
06/17
05:10
06/17/19
05:10
Upgrade
SAP rating change  »

SAP upgraded to Buy from…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Jul

E

Eni SpA

$31.24

-0.1 (-0.32%)

05:09
06/17/19
06/17
05:09
06/17/19
05:09
Upgrade
Eni SpA rating change  »

Eni SpA upgraded to Buy…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

EQNR

Equinor

$19.44

-0.06 (-0.31%)

05:08
06/17/19
06/17
05:08
06/17/19
05:08
Upgrade
Equinor rating change  »

Equinor upgraded to Hold…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Jul

ROYMY

Royal Mail

$0.00

(0.00%)

05:07
06/17/19
06/17
05:07
06/17/19
05:07
Upgrade
Royal Mail rating change  »

Royal Mail upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DOW

Dow Inc.

$51.12

-1.77 (-3.35%)

05:05
06/17/19
06/17
05:05
06/17/19
05:05
Downgrade
Dow Inc. rating change  »

Dow Inc. downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NRDBY

Nordea Bank

$0.00

(0.00%)

05:04
06/17/19
06/17
05:04
06/17/19
05:04
Downgrade
Nordea Bank rating change  »

Nordea Bank downgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.